表紙
市場調查報告書

腸胃炎 :開發中產品分析

Gastroenteritis - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 200947
出版日期 內容資訊 英文 97 Pages
訂單完成後即時交付
價格
腸胃炎 :開發中產品分析 Gastroenteritis - Pipeline Review, H1 2020
出版日期: 2020年04月30日內容資訊: 英文 97 Pages
簡介

所謂腸胃炎是指腸胃的感染疾病,症狀有胃痛、痙攣、發燒、噁心、頭痛等。 原因有受污染的飲料食品和與帶有病毒的人類接觸等。

本報告提供腸胃炎的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括最新的新聞和發表之企業和研究機關開發中的治療藥,治療藥評估等資訊。

簡介

腸胃炎 概要

治療藥的開發

  • 開發中產品;概要
  • 企業開發中的治療藥
  • 大學/機關研究中的治療藥
  • 企業開發中的產品
  • 大學/機關研究中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Nanotherapeutics Inc
  • RedHill Biopharma Ltd
  • 武田藥品工業
  • UMN Pharma Inc

藥物簡介

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC12126IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastroenteritis - Pipeline Review, H1 2020, provides an overview of the Gastroenteritis (Gastrointestinal) pipeline landscape.

Gastroenteritis is an infection of the gut. Symptoms include stomach pain, cramping, fever, nausea, and a headache. Causes of gastroenteritis include contaminated food or water, and contact with someone who has the virus. Treatment includes antibiotics, anti-emetic and anti-diarrheal medications.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastroenteritis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Gastroenteritis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastroenteritis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Gastroenteritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Unknown stages are 2, 1, 3, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Gastroenteritis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gastroenteritis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Gastroenteritis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gastroenteritis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gastroenteritis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gastroenteritis (Gastrointestinal)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gastroenteritis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gastroenteritis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Gastroenteritis - Overview
    • Gastroenteritis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Gastroenteritis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Gastroenteritis - Companies Involved in Therapeutics Development
    • Allakos Inc
    • Kyowa Kirin Co Ltd
    • Lanzhou Institute of Biological Products Co Ltd
    • Medicago Inc
    • Novo Medi Sciences Pvt Ltd
    • RedHill Biopharma Ltd
    • Regeneron Pharmaceuticals Inc
    • Takeda Pharmaceutical Co Ltd
    • UMN Pharma Inc
  • Gastroenteritis - Drug Profiles
    • AK-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antibodies for Gastroenteritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antibodies to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • benralizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dupilumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MDG-5625 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • norovirus [strains GI.1 + GII.4] (bivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ondansetron hydrochloride CR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rotavirus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-214 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • UMN-104 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Gastroenteritis - Dormant Projects
  • Gastroenteritis - Discontinued Products
  • Gastroenteritis - Product Development Milestones
    • Featured News & Press Releases
      • Nov 12, 2019: RedHill Biopharma announces publication of RHB-102 gastroenteritis phase 3 study results in JAMA
      • Oct 28, 2019: Allakos Announces Multiple Presentations from Its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting
      • Aug 05, 2019: Allakos announces AK002 met all prespecified primary and secondary endpoints in phase 2 randomized, double-blind, placebo-controlled study in patients with eosinophilic gastritis (EG) and/or eosinophilic gastroenteritis (EGE)
      • Oct 08, 2018: Allakos presents data from its eosinophilic gastrointestinal diseases program at the American College of Gastroenterology (ACG) 2018 Annual Scientific Meeting
      • Mar 27, 2018: RedHill Biopharma Announces Two Oral Presentations on BEKINDA 24 mg for acute gastroenteritis at the SAEM 2018 Annual Meeting
      • Jun 19, 2017: RedHill Biopharma to Host Conference Call on Successful Phase III Top-Line Results with BEKINDA for Acute Gastroenteritis
      • Jun 14, 2017: RedHill Biopharma Announces Successful Phase III Top-Line Results with BEKINDA for Acute Gastroenteritis
      • Apr 19, 2017: RedHill Biopharma to Host R&D Day on BEKINDA for Acute Gastroenteritis and IBS-D
      • Apr 18, 2017: RedHill Biopharma Receives Notice of Allowance for Two Additional U.S. Patents Covering BEKINDA
      • Feb 21, 2017: RedHill Biopharma Completes Treatment of Last Patient in BEKINDA Phase III Study for Acute Gastroenteritis
      • Feb 13, 2017: RedHill Biopharma Announces Enrollment of Last Patient in BEKINDA Phase III Study for Acute Gastroenteritis
      • Jan 12, 2017: RedHill Biopharma Provides Milestone Update on Bekinda
      • Nov 03, 2016: RedHill Biopharma Provides Update on Ongoing Phase III and Phase II studies with BEKINDA and Expected Timing of Top-Line Results
      • Jun 20, 2016: Takeda Initiates Worlds First Norovirus Vaccine Field Trial
      • Mar 01, 2016: RedHill Biopharma Provides Update on RHB-102
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Gastroenteritis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Gastroenteritis - Pipeline by Allakos Inc, H1 2020
  • Gastroenteritis - Pipeline by Kyowa Kirin Co Ltd, H1 2020
  • Gastroenteritis - Pipeline by Lanzhou Institute of Biological Products Co Ltd, H1 2020
  • Gastroenteritis - Pipeline by Medicago Inc, H1 2020
  • Gastroenteritis - Pipeline by Novo Medi Sciences Pvt Ltd, H1 2020
  • Gastroenteritis - Pipeline by RedHill Biopharma Ltd, H1 2020
  • Gastroenteritis - Pipeline by Regeneron Pharmaceuticals Inc, H1 2020
  • Gastroenteritis - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
  • Gastroenteritis - Pipeline by UMN Pharma Inc, H1 2020
  • Gastroenteritis - Dormant Projects, H1 2020
  • Gastroenteritis - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Gastroenteritis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020